|
Press Releases |
|
 |
|
Friday, March 7, 2025 |
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million |
OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its annual results for the year ended December 31, 2024 (the 'Year'), reporting record-high revenue and healthy net profit despite the challenging business landscape. more info >> |
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天宣佈截至截至2024年12月31日止年度(「年度」)的全年業績。 more info >> |
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙 |
专营经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司(“业聚医疗”或“集团”;股份代号:6929)今天宣布截至截至2024年12月31日止年度(“年度”)的全年业绩。 more info >> |
|
Friday, August 16, 2024 |
|
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024 |
OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2024 (the 'Reporting Period), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges. more info >> |
|
业聚医疗2024年上半年纯利达1,880万美元 |
专营经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司(「业聚医疗」或「集团」;股份代号:6929)今天宣布截至2024年6月30日止六个月(「报告期」)的中期业绩。 more info >> |
|
業聚醫療2024年上半年純利達1,880萬美元 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天宣佈截至2024年6月30日止六個月(「報告期」)的中期業績。 more info >> |
|
Wednesday, April 24, 2024 |
|
业聚医疗合资企业在中国内地启动TricValve临床试验 |
more info >> |
|
業聚醫療合資企業在中國內地啟動TricValve臨床試驗 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天公佈,其合資企業業聚培福有限公司(「業聚培福」)旗下用作治療血流動力學相關的三尖瓣功能不全和腔靜脈回流的產品——TricValve經導管雙腔靜脈瓣膜系統(「TricValve」),已於2024年4月22日在中國內地展開臨床試驗。 more info >> |
|
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China |
OrbusNeich Medical Group Holdings Limited announced today that the Group's joint venture OrbusNeich P+F Company Limited ("ON P&F") has commenced the clinical trial for the TricValve Transcatheter Bicaval Valve System ("TricValve"), to treat patients with hemodynamically relevant tricuspid insufficiency and caval reflux, on April 22, 2024 across Mainland China. more info >> |
|
Thursday, March 7, 2024 |
|
業聚醫療收入純利雙雙創新高 分別約1.54億美元及4,510萬美元 建議派發末期股息每股10港仙 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929),今天公佈截至2023年12月31日止年度的全年業績。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Investing News Network Strengthens Australian Presence with Appointment of Industry Veteran John Phillips
Jun 26, 2025 00:39 HKT/SGT
|
|
|
Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 22:27: JST
|
|
|
交易寶2025年5月亮相HOFEX 2025及HK Tech 300 Expo 助力商戶數碼轉型
Jun 25, 2025 22:21 HKT/SGT
|
|
|
PCG Showcases at HOFEX 2025 and HK Tech 300 Expo in May 2025, Driving Digital Transformation for Merchants
Jun 25, 2025 22:17 HKT/SGT
|
|
|
Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 22:27 JST
|
|
|
Galaxy Payroll Partners with CURRENC to Integrate AI and Stablecoin Technology in HR Solutions
Jun 25, 2025 20:30 HKT/SGT
|
|
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange
Jun 25, 2025 19:00: JST
|
|
|
康哲藥業建議於新加坡交易所第二上市
Jun 25, 2025 18:13 HKT/SGT
|
|
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange
Jun 25, 2025 18:00 HKT/SGT
|
|
|
從技術先驅到全球AMR第一 極智嘉商業化領跑行業
Jun 25, 2025 17:45 HKT/SGT
|
|
|
康哲药业建议于新加坡交易所第二上市
Jun 25, 2025 17:24 HKT/SGT
|
|
|
从技术先驱到全球AMR第一 极智嘉商业化领跑行业
Jun 25, 2025 17:08 HKT/SGT
|
|
|
MHI Receives Contract for Refurbishment of APM System at Singapore Changi Airport
Jun 25, 2025 14:00 JST
|
|
|
LLVisionがソウルでAR翻訳メガネの新モデル「Leion Hey2」 を世界初披露:日常生活に革新をもたらすAI翻訳
Jun 25, 2025 13:00: JST
|
|
|
交易宝2025年5月亮相HOFEX 2025及HK Tech 300 Expo 助力商户数码𨍭型
Jun 25, 2025 11:49 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|